Leading the Biomedical and Healthcare Industry to the Global Cross-border E-commerce Market; EZICON Group's precision health platform builds new business opportunities for brands to go overseas - EZICON GROUP 創易集團

The total revenue of Taiwan’s biomedical and healthcare industry will reach NT$335.4 billion in 2021.“All The Research” predicted that the global cross-border e-commerce market will grow from US$578.57 billion before the outbreak (2019) to US$2.2 trillion in 2026, with a compound annual growth rate of 17.4%. How can Taiwan’s biomedical and healthcare industry take advantage of this wave of cross-border e-commerce? The lecture ” Starting from Precision Health, Laying out Global Key New Thinking” hosted by EZICON Group (Easy International Commerce O2O Network Co., Ltd.) was held on the afternoon of June 28. It is hoped that it will be provided the solutions for Taiwan’s big health industry brands and cross-border to the Greater China market. The plan leads Taiwanese manufacturers to seize business opportunities in the 300 billion RMB health consumer market and realize the zero-distance ideal of precise health for all human beings.

EZICON Group assists Taiwan’s hundreds of healthcare brands to seize the cross-border e-commerce market

EZICON Group is actively deploying the global cross-border e-commerce market, and of course it also includes mainland China, which currently accounts for more than 50% of the global market. Shawn Chen, CEO of EZICON Group, said at the lecture: “In the past, when Taiwanese manufacturers connected to the cross-border market in mainland China, they had to handle logistics, cash flow, distribution channels, and marketing promotion by themselves, or connect with agent operators one by one. However, from 2019 Since mainland China opened the cross-border business of healthcare products, EZICON Group has assisted more than 100 manufacturers, such as Phermpep Co. Ltd., Chung Mei Pharmaceutical Co., Ltd., Nice Biotech CO., Ltd., Fecula Biotechnology Co., Ltd., and Missioncare Corp.to enter the cross-border business in mainland China. overseas e-commerce market, and create sales of more than 1 million RMB per item.”

EZICON Group creates remote health consultation services, cross-border global precision health

Shawn Chen said that, starting from the perspective of precise health, EZICON Group will combine overseas Chinese and Western physicians, nutritionists, pharmacists and other medical care teams to create “telehealth consultation” services this year. It is hoped that through the method of “online health consultation and health prescription”, Taiwan’s high-quality medical and healthcare products will be recommended to consumers in the form of “precise prescription”. Shawn Chen pointed out that the goal of precision medicine is to provide precise treatment for patients who are already sick, but the goal of “precision health” is more important. Through the mechanism of “precision health”, it can greatly reduce the development of sub-health and sub-disease groups into chronic diseases proportion, reduce medical expenditures, and increase healthy life expectancy. “Precision health” is one of the six core strategic industries, and the government also vigorously supports it through policy incentives, product guidance, regulatory adjustments, and national plans.

In this lecture of EZICON Group, a professional doctor of integrated medicine is specially invited: Dr. Andrew Hsieh, Chairman of Talented Lives International Co., Ltd., to explain the healthy solution of the digestive system from the perspective of oriental integrated medicine; and CEO of Fecula Biotechnology Co., Ltd.: Dr. Miles Chen, introducing the probiotics of Gene-Young Capsules developed from Taiwan’s Green Bananas. The two experts also shared on the spot how Taiwanese brand owners start from precision health, connect with doctors for precision health prescriptions, and expand new overseas business opportunities through the cross-border precision health platform model.